AJP - Heart and Circulatory Physiology, Vol 272, Issue 3 1173-H1181, Copyright © 1997 by American Physiological Society

ARTICLES

Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats

S. Eddahibi, B. Raffestin, I. Pham, J. M. Launay, P. Aegerter, M. Sitbon and S. Adnot
Departement de Physiologie et Institut National de la Sante et de la Recherche Medicale Unite 296, Centre Hospitalier Universitaire Henri Mondor, Creteil, France.

The aim of this study was to investigate the potential role of 5-hydroxytryptamine (5-HT) on development of pulmonary hypertension during chronic exposure to mild (15% O2) and severe (10% O2) hypoxia. In isolated lungs from normoxic rats preconstricted with U-46619, 5-HT (10(-12)-10(-8) M) induced dose-dependent vasodilation (n = 6), which was suppressed by the NO synthesis inhibitor nitro-L-arginine methyl ester (L-NAME, 10(-4) M, n = 5) and reduced by the 5-HT3-receptor antagonist MDL-7222 (10(-5) M, n = 6). The vasoconstriction that was observed with higher concentrations of 5-HT (10(-7)-10(-4) M) was inhibited by ketanserin (10(-5) M) and methiothepin (10(-5) M, n = 6 each). The vasodilator response to 5-HT was suppressed in lungs from rats exposed to 10% O2 but not 15% O2 (n = 6 each). In conscious rats, intravenous administration of 5-HT potentiated the pulmonary pressor response to acute hypoxia (10% O2, n = 5), an effect that remained unchanged after pretreatment with a 5-HT1 and a 5-HT2 antagonist (n = 4) but was attenuated after treatment with the cyclooxygenase inhibitor meclofenamate (n = 4). Treatment with 5-HT (5 nmol/h i.v. by osmotic pumps) for 2 wk in rats simultaneously exposed to 10% O2 increased pulmonary arterial pressure, right ventricular hypertrophy, and muscularization of pulmonary vessels in comparison with their hypoxic controls (n = 12 each). No changes occurred in 15% O2 hypoxic rats (n = 12 each). The present findings show that 5-HT potentiates development of pulmonary hypertension in rats exposed to chronic hypoxia.

This article has been cited by other articles:

				N. Kunichika, Y. Yu, C. V. Remillard, O. Platoshyn, S. Zhang, and J. X.-J. Yuan Overexpression of TRPC1 enhances pulmonary vasoconstriction induced by capacitative Ca2+ entry Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L962 - L969. [Abstract] [Full Text] [PDF]

				S. L. Lee, A. R. Simon, W. W. Wang, and B. L. Fanburg H2O2 signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells Am J Physiol Lung Cell Mol Physiol, September 1, 2001; 281(3): L646 - L652. [Abstract] [Full Text] [PDF]

				S. Belohlavkova, J. Simak, A. Kokesova, O. Hnilickova, and V. Hampl Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels J Appl Physiol, August 1, 2001; 91(2): 755 - 761. [Abstract] [Full Text] [PDF]

				S. Eddahibi, S. Adnot, E. Frisdal, M. Levame, M. Hamon, and B. Raffestin Dexfenfluramine-Associated Changes in 5-Hydroxytryptamine Transporter Expression and Development of Hypoxic Pulmonary Hypertension in Rats J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 148 - 154. [Abstract] [Full Text]

				S. Eddahibi, V. Fabre, C. Boni, M. P. Martres, B. Raffestin, M. Hamon, and S. Adnot Induction of Serotonin Transporter by Hypoxia in Pulmonary Vascular Smooth Muscle Cells : Relationship With the Mitogenic Action of Serotonin Circ. Res., February 19, 1999; 84(3): 329 - 336. [Abstract] [Full Text] [PDF]

				P. Egermayer, G I. Town, and A. J Peacock Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension Thorax, February 1, 1999; 54(2): 161 - 168. [Full Text]

				S. EDDAHIBI, B. RAFFESTIN, J.-M. LAUNAY, M. SITBON, and S. ADNOT Effect of Dexfenfluramine Treatment in Rats Exposed to Acute and Chronic Hypoxia Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1111 - 1119. [Abstract] [Full Text] [PDF]

				A. Keegan, I. Morecroft, D. Smillie, M. N. Hicks, and M. R. MacLean Contribution of the 5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension: Converging Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor Antagonist GR127935 Circ. Res., December 7, 2001; 89(12): 1231 - 1239. [Abstract] [Full Text] [PDF]